These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 23925886)
1. Modified opsonization, phagocytosis, and killing assays to measure potentially protective antibodies against pneumococcal surface protein A. Daniels CC; Kim KH; Burton RL; Mirza S; Walker M; King J; Hale Y; Coan P; Rhee DK; Nahm MH; Briles DE Clin Vaccine Immunol; 2013 Oct; 20(10):1549-58. PubMed ID: 23925886 [TBL] [Abstract][Full Text] [Related]
2. A modified surface killing assay (MSKA) as a functional in vitro assay for identifying protective antibodies against pneumococcal surface protein A (PspA). Genschmer KR; Accavitti-Loper MA; Briles DE Vaccine; 2013 Dec; 32(1):39-47. PubMed ID: 24211169 [TBL] [Abstract][Full Text] [Related]
3. The Modified Surface Killing Assay Distinguishes between Protective and Nonprotective Antibodies to PspA. Genschmer KR; Vadesilho CFM; McDaniel LS; Park SS; Hale Y; Miyaji EN; Briles DE mSphere; 2019 Dec; 4(6):. PubMed ID: 31826968 [TBL] [Abstract][Full Text] [Related]
4. Correlation between in vitro complement deposition and passive mouse protection of anti-pneumococcal surface protein A monoclonal antibodies. Khan N; Qadri RA; Sehgal D Clin Vaccine Immunol; 2015 Jan; 22(1):99-107. PubMed ID: 25410204 [TBL] [Abstract][Full Text] [Related]
5. The proline-rich region of pneumococcal surface proteins A and C contains surface-accessible epitopes common to all pneumococci and elicits antibody-mediated protection against sepsis. Daniels CC; Coan P; King J; Hale J; Benton KA; Briles DE; Hollingshead SK Infect Immun; 2010 May; 78(5):2163-72. PubMed ID: 20194601 [TBL] [Abstract][Full Text] [Related]
6. Protective efficacy of PspA (pneumococcal surface protein A)-based DNA vaccines: contribution of both humoral and cellular immune responses. Miyaji EN; Dias WO; Tanizaki MM; Leite LC FEMS Immunol Med Microbiol; 2003 Jun; 37(1):53-7. PubMed ID: 12770760 [TBL] [Abstract][Full Text] [Related]
7. Recombinant BCG expressing a PspA-PdT fusion protein protects mice against pneumococcal lethal challenge in a prime-boost strategy. Goulart C; Rodriguez D; Kanno AI; Lu YJ; Malley R; Leite LC Vaccine; 2017 Mar; 35(13):1683-1691. PubMed ID: 28242071 [TBL] [Abstract][Full Text] [Related]
8. PspA, a surface protein of Streptococcus pneumoniae, is capable of eliciting protection against pneumococci of more than one capsular type. McDaniel LS; Sheffield JS; Delucchi P; Briles DE Infect Immun; 1991 Jan; 59(1):222-8. PubMed ID: 1987036 [TBL] [Abstract][Full Text] [Related]
9. The pspC gene of Streptococcus pneumoniae encodes a polymorphic protein, PspC, which elicits cross-reactive antibodies to PspA and provides immunity to pneumococcal bacteremia. Brooks-Walter A; Briles DE; Hollingshead SK Infect Immun; 1999 Dec; 67(12):6533-42. PubMed ID: 10569772 [TBL] [Abstract][Full Text] [Related]
10. Pneumococcal surface protein A is expressed in vivo, and antibodies to PspA are effective for therapy in a murine model of pneumococcal sepsis. Swiatlo E; King J; Nabors GS; Mathews B; Briles DE Infect Immun; 2003 Dec; 71(12):7149-53. PubMed ID: 14638806 [TBL] [Abstract][Full Text] [Related]
11. Relationship between surface accessibility for PpmA, PsaA, and PspA and antibody-mediated immunity to systemic infection by Streptococcus pneumoniae. Gor DO; Ding X; Briles DE; Jacobs MR; Greenspan NS Infect Immun; 2005 Mar; 73(3):1304-12. PubMed ID: 15731027 [TBL] [Abstract][Full Text] [Related]
12. Novel Immunoprotective Proteins of Streptococcus pneumoniae Identified by Opsonophagocytosis Killing Screen. Wang Y; Wen Z; Pan X; Briles DE; He Y; Zhang JR Infect Immun; 2018 Sep; 86(9):. PubMed ID: 29891544 [TBL] [Abstract][Full Text] [Related]
13. The absence of PspA or presence of antibody to PspA facilitates the complement-dependent phagocytosis of pneumococci in vitro. Ren B; Li J; Genschmer K; Hollingshead SK; Briles DE Clin Vaccine Immunol; 2012 Oct; 19(10):1574-82. PubMed ID: 22855389 [TBL] [Abstract][Full Text] [Related]
15. Genetic immunization with the region encoding the alpha-helical domain of PspA elicits protective immunity against Streptococcus pneumoniae. Bosarge JR; Watt JM; McDaniel DO; Swiatlo E; McDaniel LS Infect Immun; 2001 Sep; 69(9):5456-63. PubMed ID: 11500417 [TBL] [Abstract][Full Text] [Related]
16. Mucosal immunization with an unadjuvanted vaccine that targets Streptococcus pneumoniae PspA to human Fcγ receptor type I protects against pneumococcal infection through complement- and lactoferrin-mediated bactericidal activity. Bitsaktsis C; Iglesias BV; Li Y; Colino J; Snapper CM; Hollingshead SK; Pham G; Gosselin DR; Gosselin EJ Infect Immun; 2012 Mar; 80(3):1166-80. PubMed ID: 22158740 [TBL] [Abstract][Full Text] [Related]
17. Immunization of humans with recombinant pneumococcal surface protein A (rPspA) elicits antibodies that passively protect mice from fatal infection with Streptococcus pneumoniae bearing heterologous PspA. Briles DE; Hollingshead SK; King J; Swift A; Braun PA; Park MK; Ferguson LM; Nahm MH; Nabors GS J Infect Dis; 2000 Dec; 182(6):1694-701. PubMed ID: 11069242 [TBL] [Abstract][Full Text] [Related]
18. The genetic background of Streptococcus pneumoniae affects protection in mice immunized with PspA. He X; McDaniel LS FEMS Microbiol Lett; 2007 Apr; 269(2):189-95. PubMed ID: 17355599 [TBL] [Abstract][Full Text] [Related]
19. Localization of protection-eliciting epitopes on PspA of Streptococcus pneumoniae between amino acid residues 192 and 260. McDaniel LS; Ralph BA; McDaniel DO; Briles DE Microb Pathog; 1994 Nov; 17(5):323-37. PubMed ID: 7723659 [TBL] [Abstract][Full Text] [Related]
20. Development of a conjugate vaccine against invasive pneumococcal disease based on capsular polysaccharides coupled with PspA/family 1 protein of Streptococcus pneumoniae. Lin H; Peng Y; Lin Z; Zhang S; Guo Y Microb Pathog; 2015; 83-84():35-40. PubMed ID: 25959527 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]